



**BEST AVAILABLE COPY**

JUN 22 2005

Please type a plus sign (+) inside this box

10


**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

Form 10-106 (Rev. 08-00) PTO/SB/08A (08-00)

Substitute for form 1449A/PTO				<b><i>Complete If Known</i></b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/631,967
				Filing Date	1 August 2003
				First Named Inventor	Alexander HILLISCH et al.
				Group Art Unit	1614
				Examiner Name	Unknown
(use as many sheets as necessary)				Attorney Docket Number	GULDE-0002
Sheet	1	of	2		

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

Examiner Signature		Date Considered	8/3/05
-----------------------	---	--------------------	--------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

# BEST AVAILABLE COPY

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
Sheet	2	of	2	Application Number	10/631,967
				Filing Date	1 August 2003
				First Named Inventor	Alexander HILLISCH et al.
				Group Art Unit	1614
				Examiner Name	Unknown
				Attorney Docket Number	GULDE-0002

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
BB	5	D. LOUTRADIS ET AL., "Preovulatory effects of the progesterone antagonist mifepristone (RU486) in mice," Human Reproduction, 1991, vol. 6, no.9, pages 1238-1240.			T <sup>2</sup>
	6	K. CHWALISZ ET AL., "Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium," Steroids, 2000, vol. 65, pages 741-751.			
	7	O.D. SLAYDEN ET AL., "Reversible suppression of menstruation with progesterone antagonists in rhesus macaques," Human Reproduction, 2001, vol. 16, no. 8, pages 1562-1574.			
	8	W. ELGER ET AL., "Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity," Steroids, 2000, vol. 65, pages 713-723.			
	9	W. ELGER ET AL., "Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application," J. Steroid Biochem. Molec. Biol., 1995, vol. 55, no. 3/4, pages 395-403.			
	10	E. M. COUTINHO ET AL., "Is Menstruation Obsolete?" 1999, New York, Oxford University Press.			
	11	E.ISAKSSON ET AL., "Effects of oral contraceptives on breast epithelial proliferation," Breast Cancer Research and Treatment, 2001, vol. 65, pages 163-169.			
BB	12	A. J. SPIEGEL ET AL., "Use of nonaqueous solvents in parenteral products," Journal of Pharmaceutical Sciences, October 1963, vol. 52, no.10, pages 917-927.			
	13	Von Professor Dr. H. v. Czetsch-Lindenwald, "Pentaerythruster als pharmazeutische Hilfsstoffe," Pharmazeutische Technologie, 1961, Jahrg. 23, p. 72-74.			English translation needed
	14	"Arzneimittel, Synthetische s. Chemotherapie und Pharmakotherapeutica, Arzneimittelzubereitung," pages 1-40			English translation needed
BB	15	LOUIS J. RAVIN, "Preformulation," Bioavailability and Bioequivalency Testing, Chapter 75, pages 1355-1497			
BB	16	DWIGHT L. DEARDORFF, "Ophthalmic Preparations," Medicated Applications, Chapter 86, pages 1498-1628.			
	17	ROUSSET-LUCEAF, "Nouveau medicament notamment pour le traitement des troubles dus à une insuffisance de secretion de corps jaune," Bulletin officiel de la Propriété Industrielle, no. 30 du 24 juillet 1967.			English translation needed
BB	18	G. TEUTSCH ET AL., "11Beta-substituted steroids, an original pathway to antihormones," 1988, vol. 31, no. 4B, pages 549-565.			
BB	19	XIANG-SHU FEI ET AL., "New, convenient route four trifluoromethylation of steroid molecules," J. Chem. Soc., Perkin Trans. 1, 1998, pages 1139-1142.			

Examiner Signature	Boadis	Date Considered	8/3/05
--------------------	--------	-----------------	--------